Warfarin Dosing Algorithms Underpredict Dose Requirements in Patients Requiring 7 mg Daily: A Systematic Review and

S M Saffian1,2, S B Duffull1, Dfb Wright1

  • 1School of Pharmacy, University of Otago, Dunedin, New Zealand.

Insights

Published warfarin dosing algorithms consistently underestimate the required dosage for patients needing higher doses. This meta-analysis confirms a significant underprediction across 22 algorithms for patients requiring at least 7 mg daily.

Area of Science:

  • Pharmacology
  • Clinical Pharmacy
  • Biostatistics

Background:

  • Warfarin dosing algorithms aim to personalize anticoagulant therapy.
  • Preliminary data suggest some algorithms are inaccurate for patients with high dose requirements.
  • Accurate warfarin dosing is critical for therapeutic efficacy and safety.

Purpose of the Study:

  • To determine if published warfarin dosing algorithms systematically under- or overpredict maintenance doses.
  • To specifically evaluate algorithms in patients requiring higher than average warfarin doses (≥7 mg/day).

Main Methods:

  • A meta-analysis was performed on data from Medline and Embase databases up to September 2015.
  • Included were 47 evaluations of 22 distinct warfarin dosing algorithms from 16 studies.
  • Analyzed data from 1,492 patients requiring a maintenance dose of ≥7 mg/day.

Main Results:

  • All 22 evaluated warfarin dosing algorithms demonstrated underprediction.
  • The average underprediction across algorithms was 2.3 mg/day.
  • A pooled estimate indicated 92.3% of doses were underpredicted for patients requiring ≥7 mg/day (95% CI 90.3-94.1).

Conclusions:

  • Existing warfarin dosing algorithms exhibit significant bias in predicting maintenance doses for patients with high requirements.
  • Clinical practice should account for this underprediction to ensure appropriate warfarin dosing.
  • Further research is needed to develop more accurate algorithms for diverse patient populations.

Related Concept Videos

Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
547
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
289
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
242
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
335
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.2K